je.st
news
Tag: pharmaceuticals
Enanta Pharmaceuticals Announces CHMP Positive Opinion For AbbVie's VIEKIRAX + EXVIERA Without Ribavirin For The Treatment Of Chronic Hepatitis C In Genotype 1b Patients With Compensated Cirrhosis
2016-03-02 03:39:36| drugdiscoveryonline Home Page
Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced recently that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for the use of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets) without ribavirin (RBV) in chronic hepatitis C virus (HCV) infected genotype 1b (GT1b) patients with compensated cirrhosis (Child-PughA)
Tags: with
positive
opinion
treatment
Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q4 2015 Results - Earnings Call Transcript
2016-03-02 00:47:31| Biotech - Topix.net
Good morning. My name is Victoria, and I will be your conference operator today.
Tags: results
call
ceo
earnings
Noble Financial Reaffirms "Buy" Rating for BioCryst Pharmaceuticals, Inc.
2016-02-28 04:00:20| Biotech - Topix.net
's stock had its "buy" rating restated by Noble Financial in a research report issued to clients and investors on Friday, Analyst Ratings Network.com reports. They presently have a $8.00 target price on the biotechnology company's stock.
Tags: inc
buy
rating
financial
Numis Securities Ltd Reiterates "Hold" Rating for Dechra Pharmaceuticals plc
2016-02-22 15:01:22| Automakers - Topix.net
's stock had its "hold" rating reiterated by research analysts at Numis Securities Ltd in a research note issued on Monday, AnalystRatingsNetwork.com reports. They currently have a GBX 1,095 price objective on the stock.
Tags: rating
hold
securities
plc
Ariad Pharmaceuticals, Inc. (ARIA) Scheduled to Post Quarterly Earnings on Tuesday
2016-02-22 09:52:14| Biotech - Topix.net
Ariad Pharmaceuticals, Inc. will be releasing its Q415 earnings data on Tuesday, February 23rd. Analysts expect Ariad Pharmaceuticals to post earnings of per share and revenue of $44.79 million for the quarter.
Tags: post
tuesday
scheduled
quarterly
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] next »